Cargando…
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
The randomized phase 3 ENDEAVOR study (N=929) compared carfilzomib and dexamethasone (Kd) with bortezomib and dexamethasone (Vd) in relapsed multiple myeloma (RMM). We performed a subgroup analysis from ENDEAVOR in patients categorized by number of prior lines of therapy or by prior treatment. Media...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220137/ https://www.ncbi.nlm.nih.gov/pubmed/27491641 http://dx.doi.org/10.1038/leu.2016.186 |
_version_ | 1782492570165706752 |
---|---|
author | Moreau, P Joshua, D Chng, W-J Palumbo, A Goldschmidt, H Hájek, R Facon, T Ludwig, H Pour, L Niesvizky, R Oriol, A Rosiñol, L Suvorov, A Gaidano, G Pika, T Weisel, K Goranova-Marinova, V Gillenwater, H H Mohamed, N Aggarwal, S Feng, S Dimopoulos, M A |
author_facet | Moreau, P Joshua, D Chng, W-J Palumbo, A Goldschmidt, H Hájek, R Facon, T Ludwig, H Pour, L Niesvizky, R Oriol, A Rosiñol, L Suvorov, A Gaidano, G Pika, T Weisel, K Goranova-Marinova, V Gillenwater, H H Mohamed, N Aggarwal, S Feng, S Dimopoulos, M A |
author_sort | Moreau, P |
collection | PubMed |
description | The randomized phase 3 ENDEAVOR study (N=929) compared carfilzomib and dexamethasone (Kd) with bortezomib and dexamethasone (Vd) in relapsed multiple myeloma (RMM). We performed a subgroup analysis from ENDEAVOR in patients categorized by number of prior lines of therapy or by prior treatment. Median progression-free survival (PFS) for patients with one prior line was 22.2 months for Kd vs 10.1 months for Vd, and median PFS for patients with ⩾2 prior lines was 14.9 months for Kd vs 8.4 months for Vd. For patients with prior bortezomib exposure, the median PFS was 15.6 months for Kd vs 8.1 months for Vd, and for patients with prior lenalidomide exposure the median PFS was 12.9 months for Kd vs 7.3 months for Vd. Overall response rates (Kd vs Vd) were 81.9 vs 65.5% (one prior line), 72.0 vs 59.7% (⩾2 prior lines), 71.2 vs 60.3% (prior bortezomib) and 70.1 vs 59.3% (prior lenalidomide). The safety profile in the prior lines subgroups was qualitatively similar to that in the broader ENDEAVOR population. In RMM, outcomes are improved when receiving treatment with carfilzomib compared with bortezomib, regardless of the number of prior therapy lines or prior exposure to bortezomib or lenalidomide. |
format | Online Article Text |
id | pubmed-5220137 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-52201372017-01-13 Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study Moreau, P Joshua, D Chng, W-J Palumbo, A Goldschmidt, H Hájek, R Facon, T Ludwig, H Pour, L Niesvizky, R Oriol, A Rosiñol, L Suvorov, A Gaidano, G Pika, T Weisel, K Goranova-Marinova, V Gillenwater, H H Mohamed, N Aggarwal, S Feng, S Dimopoulos, M A Leukemia Original Article The randomized phase 3 ENDEAVOR study (N=929) compared carfilzomib and dexamethasone (Kd) with bortezomib and dexamethasone (Vd) in relapsed multiple myeloma (RMM). We performed a subgroup analysis from ENDEAVOR in patients categorized by number of prior lines of therapy or by prior treatment. Median progression-free survival (PFS) for patients with one prior line was 22.2 months for Kd vs 10.1 months for Vd, and median PFS for patients with ⩾2 prior lines was 14.9 months for Kd vs 8.4 months for Vd. For patients with prior bortezomib exposure, the median PFS was 15.6 months for Kd vs 8.1 months for Vd, and for patients with prior lenalidomide exposure the median PFS was 12.9 months for Kd vs 7.3 months for Vd. Overall response rates (Kd vs Vd) were 81.9 vs 65.5% (one prior line), 72.0 vs 59.7% (⩾2 prior lines), 71.2 vs 60.3% (prior bortezomib) and 70.1 vs 59.3% (prior lenalidomide). The safety profile in the prior lines subgroups was qualitatively similar to that in the broader ENDEAVOR population. In RMM, outcomes are improved when receiving treatment with carfilzomib compared with bortezomib, regardless of the number of prior therapy lines or prior exposure to bortezomib or lenalidomide. Nature Publishing Group 2017-01 2016-08-05 /pmc/articles/PMC5220137/ /pubmed/27491641 http://dx.doi.org/10.1038/leu.2016.186 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Original Article Moreau, P Joshua, D Chng, W-J Palumbo, A Goldschmidt, H Hájek, R Facon, T Ludwig, H Pour, L Niesvizky, R Oriol, A Rosiñol, L Suvorov, A Gaidano, G Pika, T Weisel, K Goranova-Marinova, V Gillenwater, H H Mohamed, N Aggarwal, S Feng, S Dimopoulos, M A Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study |
title | Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study |
title_full | Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study |
title_fullStr | Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study |
title_full_unstemmed | Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study |
title_short | Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study |
title_sort | impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 endeavor study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220137/ https://www.ncbi.nlm.nih.gov/pubmed/27491641 http://dx.doi.org/10.1038/leu.2016.186 |
work_keys_str_mv | AT moreaup impactofpriortreatmentonpatientswithrelapsedmultiplemyelomatreatedwithcarfilzomibanddexamethasonevsbortezomibanddexamethasoneinthephase3endeavorstudy AT joshuad impactofpriortreatmentonpatientswithrelapsedmultiplemyelomatreatedwithcarfilzomibanddexamethasonevsbortezomibanddexamethasoneinthephase3endeavorstudy AT chngwj impactofpriortreatmentonpatientswithrelapsedmultiplemyelomatreatedwithcarfilzomibanddexamethasonevsbortezomibanddexamethasoneinthephase3endeavorstudy AT palumboa impactofpriortreatmentonpatientswithrelapsedmultiplemyelomatreatedwithcarfilzomibanddexamethasonevsbortezomibanddexamethasoneinthephase3endeavorstudy AT goldschmidth impactofpriortreatmentonpatientswithrelapsedmultiplemyelomatreatedwithcarfilzomibanddexamethasonevsbortezomibanddexamethasoneinthephase3endeavorstudy AT hajekr impactofpriortreatmentonpatientswithrelapsedmultiplemyelomatreatedwithcarfilzomibanddexamethasonevsbortezomibanddexamethasoneinthephase3endeavorstudy AT facont impactofpriortreatmentonpatientswithrelapsedmultiplemyelomatreatedwithcarfilzomibanddexamethasonevsbortezomibanddexamethasoneinthephase3endeavorstudy AT ludwigh impactofpriortreatmentonpatientswithrelapsedmultiplemyelomatreatedwithcarfilzomibanddexamethasonevsbortezomibanddexamethasoneinthephase3endeavorstudy AT pourl impactofpriortreatmentonpatientswithrelapsedmultiplemyelomatreatedwithcarfilzomibanddexamethasonevsbortezomibanddexamethasoneinthephase3endeavorstudy AT niesvizkyr impactofpriortreatmentonpatientswithrelapsedmultiplemyelomatreatedwithcarfilzomibanddexamethasonevsbortezomibanddexamethasoneinthephase3endeavorstudy AT oriola impactofpriortreatmentonpatientswithrelapsedmultiplemyelomatreatedwithcarfilzomibanddexamethasonevsbortezomibanddexamethasoneinthephase3endeavorstudy AT rosinoll impactofpriortreatmentonpatientswithrelapsedmultiplemyelomatreatedwithcarfilzomibanddexamethasonevsbortezomibanddexamethasoneinthephase3endeavorstudy AT suvorova impactofpriortreatmentonpatientswithrelapsedmultiplemyelomatreatedwithcarfilzomibanddexamethasonevsbortezomibanddexamethasoneinthephase3endeavorstudy AT gaidanog impactofpriortreatmentonpatientswithrelapsedmultiplemyelomatreatedwithcarfilzomibanddexamethasonevsbortezomibanddexamethasoneinthephase3endeavorstudy AT pikat impactofpriortreatmentonpatientswithrelapsedmultiplemyelomatreatedwithcarfilzomibanddexamethasonevsbortezomibanddexamethasoneinthephase3endeavorstudy AT weiselk impactofpriortreatmentonpatientswithrelapsedmultiplemyelomatreatedwithcarfilzomibanddexamethasonevsbortezomibanddexamethasoneinthephase3endeavorstudy AT goranovamarinovav impactofpriortreatmentonpatientswithrelapsedmultiplemyelomatreatedwithcarfilzomibanddexamethasonevsbortezomibanddexamethasoneinthephase3endeavorstudy AT gillenwaterhh impactofpriortreatmentonpatientswithrelapsedmultiplemyelomatreatedwithcarfilzomibanddexamethasonevsbortezomibanddexamethasoneinthephase3endeavorstudy AT mohamedn impactofpriortreatmentonpatientswithrelapsedmultiplemyelomatreatedwithcarfilzomibanddexamethasonevsbortezomibanddexamethasoneinthephase3endeavorstudy AT aggarwals impactofpriortreatmentonpatientswithrelapsedmultiplemyelomatreatedwithcarfilzomibanddexamethasonevsbortezomibanddexamethasoneinthephase3endeavorstudy AT fengs impactofpriortreatmentonpatientswithrelapsedmultiplemyelomatreatedwithcarfilzomibanddexamethasonevsbortezomibanddexamethasoneinthephase3endeavorstudy AT dimopoulosma impactofpriortreatmentonpatientswithrelapsedmultiplemyelomatreatedwithcarfilzomibanddexamethasonevsbortezomibanddexamethasoneinthephase3endeavorstudy |